Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells
Authors:
- 28 February 2013
- journal article
- Published by Spandidos Publications in Oncology Reports
- Vol. 29 (5) , 1841-1850
Abstract
Retinoblastoma (RB) is a challenging disease that affects mostly young children. Chemical therapy has been shown to have limitations during clinical practice, principally because of the ability of RB to become resistant to the treatment. Nevertheless, chemotherapy is still the main treatment for RB, and immunotherapy has become a promising treatment for most solid tumors with fewer side effects than traditional therapies. In this study, we explored the antitumor effects of cytokine-induced killer (CIK) cells co-cultured with dendritic cells (DCs) pulsed with complete tumor antigens (DC-Ag). Cytotoxicity and specificity were evaluated on an RB cell line (RB-Y79), on a human normal retina cell line (hTERT-RPE1) and a carboplatin-resistant RB cell line. Our results showed that CIK differentiation and cytotoxicity were enhanced by co-culturing CIKs with DC-Ag. Moreover, the co-culture improved the CIK proliferation rate by increasing IL-6 and decreasing IL-10 levels in the culture medium. Furthermore, the use of DC-Ag-CIK cells had little effect on normal retinal cells but high cytotoxicity on RB cells even on carboplatin-resistant retinoblastoma cells. This is the first study showing that DC cells pulsed with the complete tumor antigen improve proliferation, differentiation and cytotoxic activity of CIKs specific not only for RB but also for the chemotherapy-resistant form of the malady. Thus highly efficient immunotherapy based on DC-Ag-CIK cells may be a potential effective and safe mean of treating RB especially to patients where traditional chemical therapy has failed.Keywords
This publication has 44 references indexed in Scilit:
- Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocolCytotherapy, 2012
- Outcome, Pathologic Findings, and Compliance in Orbital Retinoblastoma (International Retinoblastoma Staging System Stage III) Treated with Neoadjuvant ChemotherapyOphthalmology, 2012
- RetinoblastomaThe Lancet, 2012
- Current Update on RetinoblastomaInternational Ophthalmology Clinics, 2011
- Preliminary Experience in Treatment of Papillary and Macular Retinoblastoma: Evaluation of Local Control and Local Complications After Treatment With Linear Accelerator-Based Stereotactic Radiotherapy With Micromultileaf Collimator as Second-Line or Salvage Treatment After ChemotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Delay in the diagnosis of retinoblastoma in ChinaActa Ophthalmologica, 2010
- Immunotherapy of Malignant Disease with Tumor Antigen–Specific Monoclonal AntibodiesClinical Cancer Research, 2010
- Expression of the Multi-Drug Resistance Proteins and the Pregnane X Receptor in Treated and Untreated RetinoblastomaCurrent Eye Research, 2009
- Global issues and opportunities for optimized retinoblastoma carePediatric Blood & Cancer, 2007
- Retinoblastoma incidence and survival in European children (1978–1997). Report from the Automated Childhood Cancer Information System projectEuropean Journal of Cancer, 2006